Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study’s dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS)…
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
calendar_today
September 17, 2026
domain
abbvie